Importantly, UBC13 was also shown to be lower in ovarian cancer samples that had a shorter disease-free survival after paclitaxel-containing therapy, leading to the conclusion that low UBC13 and high CHFR might be mediators of paclitaxel resistance in ovarian cancer [35]. This evidence concerns the gene UBE2N and ovarian cancer.